Ryan E. Wiegand

7.3k total citations · 2 hit papers
130 papers, 3.4k citations indexed

About

Ryan E. Wiegand is a scholar working on Infectious Diseases, Parasitology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ryan E. Wiegand has authored 130 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Infectious Diseases, 44 papers in Parasitology and 33 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ryan E. Wiegand's work include Parasites and Host Interactions (38 papers), Global Maternal and Child Health (28 papers) and Malaria Research and Control (22 papers). Ryan E. Wiegand is often cited by papers focused on Parasites and Host Interactions (38 papers), Global Maternal and Child Health (28 papers) and Malaria Research and Control (22 papers). Ryan E. Wiegand collaborates with scholars based in United States, Kenya and Switzerland. Ryan E. Wiegand's co-authors include Christopher J. McDougle, David J. Posey, W. Evan Secor, Susan P. Montgomery, Alexandra M. Oster, Kimberly A. Stigler, Dyson Mwandama, Naomi B. Swiezy, Don P. Mathanga and Thayne L. Sweeten and has published in prestigious journals such as Nature Communications, Journal of the American Statistical Association and PLoS ONE.

In The Last Decade

Ryan E. Wiegand

128 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Public health impact of covid-19 vaccines in the US: observational study

2022 116 citations Ryan E. Wiegand et al. profile →
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023

2023 76 citations Ruth Link‐Gelles, Allison Avrich Ciesla et al. MMWR Morbidity and Mortality Weekly Report profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryan E. Wiegand United States	36	940	897	812	587	529	130	3.4k
Kenji Hirayama Japan	45	1.3k 1.4×	2.6k 2.9×	635 0.8×	1.1k 1.9×	274 0.5×	266	6.4k
Isaac I. Bogoch Canada	38	2.0k 2.1×	1.2k 1.3×	844 1.0×	749 1.3×	432 0.8×	195	5.3k
Andrea Sylvia Winkler Germany	37	737 0.8×	412 0.5×	692 0.9×	574 1.0×	395 0.7×	196	4.5k
Beatriz Muñoz United States	28	747 0.8×	542 0.6×	297 0.4×	874 1.5×	460 0.9×	56	4.3k
Christian Bottomley United Kingdom	38	1.2k 1.3×	1.1k 1.3×	332 0.4×	1.5k 2.6×	1.5k 2.9×	137	5.8k
Sarah Donegan United Kingdom	26	375 0.4×	1.4k 1.5×	415 0.5×	340 0.6×	412 0.8×	49	3.2k
Alfred K. Njamnshi Cameroon	30	1.1k 1.1×	358 0.4×	327 0.4×	310 0.5×	529 1.0×	163	2.7k
Alison M. Elliott United Kingdom	48	2.4k 2.5×	1.3k 1.4×	1.6k 2.0×	2.0k 3.4×	1.5k 2.8×	229	8.5k
Weidong Zhang China	31	656 0.7×	455 0.5×	544 0.7×	593 1.0×	171 0.3×	209	4.6k
Charles R. Woods United States	37	910 1.0×	702 0.8×	136 0.2×	1.3k 2.3×	406 0.8×	127	5.7k

Countries citing papers authored by Ryan E. Wiegand

Since Specialization

Citations

This map shows the geographic impact of Ryan E. Wiegand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan E. Wiegand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan E. Wiegand more than expected).

Fields of papers citing papers by Ryan E. Wiegand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan E. Wiegand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan E. Wiegand. The network helps show where Ryan E. Wiegand may publish in the future.

Co-authorship network of co-authors of Ryan E. Wiegand

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan E. Wiegand. A scholar is included among the top collaborators of Ryan E. Wiegand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan E. Wiegand. Ryan E. Wiegand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rowley, Elizabeth, Patrick K. Mitchell, Duck‐Hye Yang, et al.. (2025). Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study. JMIR Formative Research. 9. e58981–e58981.

Wiegand, Ryan E., Bruce Fireman, Morgan Najdowski, et al.. (2024). Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection. Nature Communications. 15(1). 10062–10062. 2 indexed citations

Reses, Hannah E., Heather Dubendris, Emily Wong, et al.. (2024). Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024. MMWR Morbidity and Mortality Weekly Report. 73(46). 1052–1057. 4 indexed citations

Straily, Anne, Ryan E. Wiegand, Nnaemeka C. Iriemenam, et al.. (2023). Schistosomiasis Seroprevalence among Children Aged 0–14 Years in Nigeria, 2018. American Journal of Tropical Medicine and Hygiene. 110(1). 90–97. 1 indexed citations

Wong, Emily, Ryan E. Wiegand, Hannah E. Reses, et al.. (2023). Effectiveness of Up-to-Date COVID-19 Vaccination in Preventing SARS-CoV-2 Infection Among Nursing Home Residents — United States, November 20, 2022–January 8, 2023. MMWR Morbidity and Mortality Weekly Report. 72(25). 690–693. 6 indexed citations

Kahn, Rebecca, Daniel R. Feikin, Ryan E. Wiegand, & Marc Lipsitch. (2023). EXAMINING BIAS FROM DIFFERENTIAL DEPLETION OF SUSCEPTIBLES IN VACCINE EFFECTIVENESS ESTIMATES IN SETTINGS OF WANING. American Journal of Epidemiology. 193(1). 232–234. 1 indexed citations

Fleming-Dutra, Katherine E., Allison Avrich Ciesla, Lauren E. Roper, et al.. (2023). Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023. MMWR Morbidity and Mortality Weekly Report. 72(7). 177–182. 11 indexed citations

Ciesla, Allison Avrich, Ryan E. Wiegand, Zachary Smith, et al.. (2023). Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods. Open Forum Infectious Diseases. 10(5). ofad187–ofad187. 7 indexed citations

Kompaniyets, Lyudmyla, Ryan E. Wiegand, Lara Bull–Otterson, et al.. (2023). Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period—United States, 1 January 2022 to 31 March 2022. Clinical Infectious Diseases. 76(10). 1753–1760. 7 indexed citations

10.

Link‐Gelles, Ruth, Allison Avrich Ciesla, Lauren E. Roper, et al.. (2023). Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023. MMWR Morbidity and Mortality Weekly Report. 72(5). 119–124. 76 indexed citations breakdown →

11.

Morice, Ana, María Paz Ade, Gloria Rey-Benito, et al.. (2023). Lessons learned from the implementation of integrated serosurveillance of communicable diseases in the Americas. Revista Panamericana de Salud Pública. 47. 1–1. 5 indexed citations

12.

Chin, Elizabeth T., Yifan Zhang, Elizabeth E. Long, et al.. (2022). Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study. Clinical Infectious Diseases. 75(1). e838–e845. 17 indexed citations

13.

Rivera, Hilda N., Isabel McAuliffe, Ryan E. Wiegand, et al.. (2022). Evaluation of the Performance of Ortho T. cruzi ELISA Test System for the Detection of Antibodies to Trypanosoma cruzi. Journal of Clinical Microbiology. 60(8). e0013422–e0013422. 5 indexed citations

14.

Wiegand, Ryan E., W. Evan Secor, Fiona Fleming, et al.. (2021). Associations between infection intensity categories and morbidity prevalence in school-age children are much stronger for Schistosoma haematobium than for S. mansoni. PLoS neglected tropical diseases. 15(5). e0009444–e0009444. 19 indexed citations

15.

Collins, Emma, Abdoul Habib Béavogui, James Orsborne, et al.. (2019). The relationship between insecticide resistance, mosquito age and malaria prevalence in Anopheles gambiae s.l. from Guinea. Scientific Reports. 9(1). 8846–8846. 43 indexed citations

16.

Steinhardt, Laura C., Daniel Impoinvil, Kimberly E. Mace, et al.. (2016). Effectiveness of insecticide-treated bednets in malaria prevention in Haiti: a case-control study. The Lancet Global Health. 5(1). e96–e103. 41 indexed citations

17.

Neely, Michael, Richard M. Rutstein, Gloria P. Heresi, et al.. (2013). Use of Nucleoside Reverse Transcriptase Inhibitor–only Regimens in HIV-infected Children and Adolescents. The Pediatric Infectious Disease Journal. 32(9). e370–e376. 1 indexed citations

18.

Lee, Teresa, Linda Gaul, Kate Klein, et al.. (2013). Outbreaks of Cyclosporiasis — United States, June–August 2013. MMWR Morbidity and Mortality Weekly Report. 62(43). 11 indexed citations

19.

Kapetanovic, Suad, et al.. (2011). Associations of Medically Documented Psychiatric Diagnoses and Risky Health Behaviors in Highly Active Antiretroviral Therapy-Experienced Perinatally HIV-Infected Youth. AIDS Patient Care and STDs. 25(8). 493–501. 36 indexed citations

20.

Stigler, Kimberly A., et al.. (2004). A Naturalistic Retrospective Analysis of Psychostimulants in Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology. 14(1). 49–56. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact